For Germany alone, current forecasts predict 2.8 million people with dementia by 2050. At the same time the age is the main risk factor for developing neurodegenerative diseases. The problem: people with neurodegenerative diseases are considered to require a lot of care and are increasing due to demographic change. This is accompanied by increasing cost pressure on health insurance companies, from the burdens on Not to mention the patients themselves as well as their relatives and society. Urgent We are therefore looking for an effective and inexpensive test that can identify early indicators of neurodegenerative disease detect illnesses. Based on these early diagnoses, affected people could be treated in a timely manner change their lifestyle and receive tailored therapies before irreversible brain damage occurs.

It is thanks to Klaus Gerwert that such a test now exists.  The “immuno-infrared sensor” developed by his company betaSENSE measures the structural changes of proteins in body fluids and detects structural misfolding long before the first symptoms of disease appear. Thanks to the innovation, doctors and those affected gain valuable time to be able to take countermeasures at an early stage. In order to develop the test to market maturity. In mid-2020, iR Diagnostic IP holding was founded as a spin-off from the Ruhr University Bochum and won quickly investors for Klaus Gerwert´s vision. This later became betaSENSE GmbH. Gerwert hopes that health insurance companies include the test in their offering and in a few years it will become part of regular preventive examinations. Thanks to Gerwert’s invention and the new, very promising medications, the disease progress can successfully be  influenced. This enables more people to live a healthy life, even in old age and dignity.